Day Pitney Deepens Intellectual Property Bench in Boston with the Addition of John C. Serio

Day Pitney LLP is pleased to welcome John C. Serio as Of Counsel in the firm’s Intellectual Property and Technology practice.  Based in the Boston office, Serio’s arrival marks another strategic step in the continued expansion of both the firm’s Boston footprint and its Intellectual Property capabilities. With deep experience in patent, technology and regulatory law, particularly in the biotech, medtech, and pharmaceutical sectors, Serio enhances a growing team that includes recent Boston-based additions Dr. Christopher Cowles and Dr. Richard Emmons—both of whom bring advanced scientific backgrounds and a focus on complex patent strategy and prosecution.  

"John brings a rare and valuable combination of patent acumen and regulatory insight to our team," remarked Carrie Webb Olson, chair of Day Pitney's Intellectual Property and Technology practice. "His extensive work across a variety of industry sectors—advising on patent strategy, FDA product approvals, and cross-border licensing—significantly strengthens our ability to guide clients through the full arc of innovation, from development and acquisition to regulatory compliance and market entry."

In his new role, Serio will advise clients in the food and drug, medical device, healthcare, and scientific equipment sectors on a wide range of intellectual property and regulatory matters, including U.S. and international patent prosecution, litigation, licensing, IP strategy, and IP issues tied to product development and commercialization. He will also provide comprehensive guidance on FDA compliance and regulatory strategy, covering approvals, labeling, marketing, manufacturing, and clinical trial agreements for drugs, devices, and related products. 

Over the course of his career, Serio has built a national and international practice advising both emerging and established life sciences companies on complex patent and regulatory challenges. He has led the prosecution of high-value patent portfolios—many of which have been successfully enforced or licensed—and regularly advises on risk mitigation strategies tied to product pipelines and technology acquisitions. Serio has deep experience counseling on FDA-regulated products, not only in the pharmaceutical and medical device space but also across food, dietary supplements, cosmetics, and consumer goods. A frequent speaker and published authority on FDA and patent law, he is also recognized for his insight on clinical trial regulation and the evolving role of digital media in pharmaceutical advertising.

An active member of the legal and life sciences communities, Serio is involved with the Boston Patent Law Association and the Boston Bar Association. He is an accredited speaker with the American College of Pharmaceutical Education and has delivered continuing education programs and written extensively for professional audiences on FDA compliance and pharmaceutical IP issues. Serio earned his J.D. from Western New England College School of Law and his B.S. from the University of Rhode Island College of Pharmacy. He is admitted to practice in Massachusetts’ state and federal courts and is a registered patent attorney. Serio is joined by Christopher Head, Patent Associate and other highly experienced legal professionals.

No aspect of this advertisement has been approved by the highest court of any state. Prior results do not guarantee a similar outcome.